AI-generated summary
The document discusses the medical history and treatment journey of a 76-year-old woman diagnosed with ovarian cancer and multiple abdominal metastases. Initially, she underwent chemotherapy with carboplatin and paclitaxel for five cycles, followed by maintenance therapy with olaparib for five years. In April 2024, a CT scan indicated a recurrence, leading to additional chemotherapy with carboplatin, paclitaxel, and bevacizumab. However, she experienced an allergic reaction to carboplatin, and subsequent treatments with cisplatin did not yield positive results, as her CA125 levels continued to rise. By August 2024, she resumed olaparib but faced persistent elevation in CA125 levels. As of January 2025, she stopped olaparib and began taking letrozole, later adding niraparib, but her CA125 levels exceeded 1000. Currently, she is in a challenging situation with poor health indicators and recent irregular bleeding, raising concerns about her treatment options and the potential for intraperitoneal hyperthermic perfusion therapy. She seeks expert guidance on the next steps in her treatment plan.